19 -12 (62) 2023 — Aghababyan I.R., Djabbarova N.M. — ROLE OF BIOIMPEDANCEMETRY IN STUDYING THE PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE

ROLE OF BIOIMPEDANCEMETRY IN STUDYING THE PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE

Aghababyan I.R., Samarkand State Medical University Uzbekistan

Djabbarova N.M., Samarkand State Medical University Uzbekistan

Sadykova Sh.Sh. Samarkand State Medical University Uzbekistan

Resume

The aim of this scientific study was to evaluate the amount of total and visceral fat using bioimpedancemetry and to determine their importance in the pathogenesis of non-alcoholic fatty liver disease.

63 patients with non-alcoholic fatty liver disease in the stage of steatosis were examined. To verify the diagnosis, in addition to general clinical data, we used the results of ultrasound examination of the liver, the determination of liver enzymes in blood serum and lipids. Bioimpedance measurements were performed on all patients to assess body fat (total and visceral fat) and muscle mass.

The examined patients revealed significant changes in the blood lipid spectrum towards an increase in total cholesterol, low-density lipoproteins and triglycerides, and a decrease in the level of high-density lipoproteins. When analyzing bioimpedansometry data, a significant increase in the amount of total and visceral fat was noted, as well as a tendency towards a decrease in muscle mass.

It has been established that the development of NAFLD is statistically significantly associated with an increase in the amount of adipose tissue (total and visceral fat) and a decrease in muscle mass associated with dyslipidemia. An increase in the amount of adipose tissue, including due to visceral fat, and a decrease in muscle mass are considered risk factors for the development of NAFLD.

Key words: component composition of the body, total fat, visceral fat, pathogenesis of non-alcoholic fatty liver disease

First page

91

Last page

96

For citation: Aghababyan I.R., Djabbarova N.M., Sadykova Sh.Sh. – ROLE OF BIOIMPEDANCEMETRY IN STUDYING THE PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE //New Day in Medicine 2023 12(62): 91-96 https://newdaymedicine.com/index.php/2023/12/10/l-573/

LIST OF REFERENCES:

1. Агабабян Ирина Рубеновна, Ким Галина Сафроновна Роль статинов в лечении неалкогольной жировой болезни печени // Вопросы науки и образования. 2023;1(166). URL: https://cyberleninka.ru/article/n/rol-statinov-v-lechenii-nealkogolnoy-zhirovoy-bolezni-pecheni
2. Агабабян Ирина Рубеновна, Джаббарова Нафиса Мамасолиевна, Рофеев Мумин Шамсиевич, Назарова Зухра Шариповна, Пулатова Кристина Самвеловна Метаболический синдром как один из основных факторов развития артериальной гипертонии // Достижения науки и образования. 2019;10(51):54-58.
3. Белоусова Л.Н., Евдокимова Л.С., Евдокимов Д.С., Серкова М.Ю., Бакулин И.Г. Стеатоз печени: поиск новых факторов риска. Биоимпедансный анализ и эластометрия при проведении скрининга // Доктор.Ру. 2018;7(151):6-10.
4. Kim D., Kim W.R. Nonobese Fatty Liver Disease // Clin. Gastroenterol. Hepatol. 2017;15:474-485.
5. Вахрушев Я.М. Оценка эффективности дифференцированной терапии неалкогольной жировой болезни печени /Я.М. Вахрушев, Е.В. Сучкова, А.П. Лукашевич //Терапевтический архив. 2020;92(2):29-33.
6. Ивашкин В.Т. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования Direg 2 // В.Т.Ивашкин, О.М.Драпкина, И.В.Маев и др. / Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2015;Т.XXV(6):31-41.
7. Подчиненова Д.В., Самойлова Ю.Г., Олейник О.А., Кобякова О.С. Роль биоимпедансометрии в диагностике висцерального ожирения у детей и подростков // Медицина: теория и практика. 2019;4:426.
8. Сучкова Е.В. Неалкогольная жировая болезнь печени (патогенез, диагностика, лечение) монография / Е.В. Сучкова, А.П. Лукашевич, Я.М. Вахрушев. – Ижевск, 2021;122.
9. Agababyan I., Sh S. Pleyotropic Effects of Statins Non-Alcoholic Fat Disease of the Liver Non-Alcoholic Steatohepatitis // RECIPE Учредители: УП” Профессиональные издания”. 2022;25(2):194-199.
10. Kim D., Kim W.R. Nonobese Fatty Liver Disease // Clin. Gastroenterol. Hepatol. 2017;15:474-485.
11. Madeira F.B., Silva A.A., Veloso H.F., Goldani M.Z., Kac G., Cardoso V.C., et al. Normal Weight Obesity Is Associated with Metabolic Syndrome and Insulin Resistance in Young Adults from a Middle-Income Country // PLoS One 2013;8(3):e60673. https://doi. org/10.1371/journal.pone.0060673.
12. Mayevskaya M.V. An effect of ursodeoxycholic acid on inflammation, steatosis and liver fibrosis and atherogenesis factors in patients with nonalcoholic fatty liver disease: Results of the USPEH Study / M.V.Mayevskaya, M.Yu.Nadinskaia, V.D.Lunkov et al. // Russian J. of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):22-29. (In Russ.) doi:10.22416/1382–4376–2019–29–6–22–29.
13. Nonalcoholic fatty liver disease: a systematic review / M.E.Rinella / JAMA. 2015;313:2263-2273.
14. Oliveros E., Somers V.K., Sochor O., Goel K., Lopez-Jimenez F. The concept of normal weight obesity // Progress in Cardiovascular Diseases. 2014;56(4):426-33. doi: 10.1016/j.pcad.2013.10.003.
15. Rubenovna A.I. et al. Analysis of the effect of food stereotypes on disease in liver circuit disease // Asian journal of pharmaceutical and biological research. 2022;11:2.